Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Combination Therapy in Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02436707Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2015
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, selinexor in B cell lymphoma, sponsored by Canadian Cancer Trials Group. Started Oct 2015; status: active, not recruiting.
02
Drugs
ibrutinibselinexor
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02436707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436707.